Overview

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects (good and bad) AZD1775 used in combination with carboplatin and paclitaxel will have on participants and their cancer.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Treatments:
Adavosertib
Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel